Cetuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Cetuximab
- Cetuximab: From Colorectal and Squamous Cell Carcinoma to Bronchial Adenomas/Carcinoids (Childhood)
Cetuximab: From Colorectal and Squamous Cell Carcinoma to Bronchial Adenomas/Carcinoids (Childhood)
One-Sentence Summary
Cetuximab is an anti-EGFR antibody originally used for colorectal cancer and squamous cell carcinomas, including those of the head and neck. The TxGNN model predicts it may be effective for bronchial adenomas/carcinoids (childhood) with a very high score. However, no clinical trials and no publications support this top-ranked prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Colorectal cancer and squamous cell carcinoma (colon, pharyngeal, laryngeal). The Singapore licence record contains no indication text, so these come from the knowledge-graph indication data |
| Predicted New Indication | Bronchial adenomas/carcinoids (childhood) |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. From known pharmacology, cetuximab is a monoclonal antibody that binds the epidermal growth factor receptor (EGFR). Its efficacy in EGFR-expressing colorectal cancer and in squamous cell carcinoma of the head and neck is established, and mechanistically it may be applicable to other EGFR-expressing tumours.
A plausible link to bronchial carcinoids would be EGFR expression in neuroendocrine or bronchial tumours. This is speculative and not supported by any trial or publication retrieved for this report. The high score is a graph-based prediction only. Childhood bronchial carcinoids are also very different from the adult epithelial cancers for which cetuximab is approved.
Other predicted indications reviewed (for context):
| Predicted Indication | Evidence Level | Evidence Summary |
|---|---|---|
| Pre-malignant neoplasm | L1 (assigned conservatively; directly relevant evidence is phase 2) | One completed phase II trial of single-agent cetuximab in high-risk premalignant upper aerodigestive lesions (NCT00524017, n=35). The phase 3 trial found is in established colorectal cancer, not premalignant disease |
| Cystic neoplasm | L2 | Phase I/II trial in adenoid cystic carcinoma (NCT01192087) and a phase II study in salivary gland carcinomas (PMID 18804410), with limited activity. The evidence applies to specific subtypes only |
| Odontogenic cyst | L4 | Two case reports of carcinoma arising in the cyst, which concern the malignant transformation, not the benign cyst |
| Ductal or ductular proliferation | L4 | Literature is mostly on pancreatic cancer and is preclinical or indirect. KRAS-driven disease is a known resistance context for anti-EGFR antibodies |
| Other labels (chondroid hamartoma, non-seminomatous lesion, testis/paratestis tumour, thyroglossal duct cyst, epiglottis neoplasm) | L5 | No supporting evidence retrieved. Epiglottis neoplasm overlaps with the existing laryngeal and head and neck squamous cell carcinoma indications |
Clinical Trial Evidence
Currently no related clinical trials are registered for bronchial adenomas/carcinoids (childhood).
Literature Evidence
Currently no related literature is available for bronchial adenomas/carcinoids (childhood).
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13629P | Erbitux 5mg/ml | Infusion, solution | Not stated in the licence record |
Manufacturer: Merck Healthcare KGaA. Status: valid. Route: injectable only.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions. Literature notes skin disorders and severe infusion reactions as recognised effects |
| Handling Protection | Please refer to the package insert and local handling policy |
Safety Considerations
- Drug Interactions: 20 interaction records were found. Two are rated Major: aminolevulinic acid and thalidomide. Most others are rated Moderate:
- Proton pump inhibitors (rabeprazole, omeprazole, dexlansoprazole, esomeprazole, lansoprazole, pantoprazole)
- Chemotherapy agents (capecitabine, carboplatin, cisplatin, fluorouracil, oxaliplatin, omacetaxine mepesuccinate)
- Photosensitising agents (methoxsalen, topical aminolevulinic acid, methyl aminolevulinate, verteporfin)
- Idelalisib
- Target: cetuximab binds the epidermal growth factor receptor (EGFR).
Package insert warnings and contraindications were not available, so please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction rests on a model score alone, with no trials or publications. There is no mechanistic data to back the EGFR hypothesis in childhood bronchial carcinoids, and the score alone does not justify moving forward.
To proceed, the following is needed:
- Package insert warnings and contraindications (from the HSA website), which is a blocking gap for safety screening
- Mechanism-of-action data (from DrugBank)
- Preclinical or clinical evidence of EGFR expression and anti-EGFR response in bronchial carcinoids
- If the aim is a better-supported direction, consider evaluating the lower-ranked pre-malignant neoplasm (NCT00524017) or salivary gland/adenoid cystic carcinoma (NCT01192087, PMID 18804410) predictions separately, with attention to safety in chemoprevention populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.